NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University
January 03 2024 - 7:30AM
NightHawk Biosciences (NYSE American:
NHWK) (“NightHawk” or the “Company”), an integrated
contract development and manufacturing organization (CDMO), today
announced its Scorpius BioManufacturing subsidiary
(“Scorpius”) has commenced work on a contract that it was
awarded by a leading university to develop and manufacture a novel
biologic targeting substance use disorder, which includes drug,
alcohol and opioid addiction.
Jeff Wolf, CEO of NightHawk, commented, “We are
honored to have been awarded this multi-million dollar contract by
one of the foremost research universities in the United States.
Scorpius was selected due to its process development and large
molecule manufacturing expertise, as well as its flexibility and
dedication to customer service. We are off to a strong start and
look forward to expanding this relationship into additional
programs in 2024 and beyond. Overall, we could not be more excited
by the traction and growing pipeline within Scorpius.”
NightHawk Biosciences,
Inc.NightHawk Biosciences, through its Scorpius
BioManufacturing subsidiary, is an integrated contract development
and manufacturing organization (CDMO) focused on rapidly advancing
biologic and cell therapy programs to the clinic and beyond.
Scorpius offers a broad array analytical testing, process
development, and manufacturing services to pharmaceutical and
biotech companies at its state-of-the art facilities in San
Antonio, TX. With an experienced team and new, purpose-built U.S.
facilities, Scorpius is dedicated to transparent collaboration and
flexible, high-quality biologics biomanufacturing. For more
information, please visit: www.nighthawkbio.com or
www.scorpiusbiologics.com, and also follow us on Twitter.
Forward Looking StatementThis
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions, and include statements such as expanding the
relationship with the university into additional programs in 2024
and beyond Important factors that could cause actual results to
differ materially from current expectations include, among others,
the Company’s ability to generate future revenue from manufacturing
contracts, the Company’s ability to continue to grow revenue,
leverage fixed costs and achieve long-term profitability; the
Company’s ability to create substantial shareholder value as a
pure-play CDMO in an underserved marketplace; the Company’s
financing needs, its cash balance being sufficient to sustain
operations and its ability to raise capital when needed, the
Company’s ability to successfully operate as a CDMO the ability to
obtain regulatory approval or to comply with ongoing regulatory
requirements, regulatory limitations relating to the Company’s
ability to successfully promote its services and compete as a
pure-play CDMO, and other factors described in the Company’s annual
report on Form 10-K for the year ended December 31, 2022,
subsequent quarterly reports on Form 10-Qs and any other filings
the Company makes with the SEC. The information in this
presentation is provided only as of the date presented, and the
Company undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017investorrelations@nighthawkbio.com
Nighthawk Biosciences (AMEX:NHWK)
Historical Stock Chart
From Apr 2024 to May 2024
Nighthawk Biosciences (AMEX:NHWK)
Historical Stock Chart
From May 2023 to May 2024